Publikationen in Zusammenarbeit mit Forschern von Claude Bernard University Lyon 1 (12)

2024

  1. Hypomagnesaemia with varying degrees of extrarenal symptoms as a consequence of heterozygous CNNM2 variants

    Scientific Reports, Vol. 14, Núm. 1

2021

  1. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

    Targeted Oncology, Vol. 16, Núm. 4, pp. 485-492

2020

  1. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

    The Lancet, Vol. 396, Núm. 10262, pp. 1574-1584

2019

  1. Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy – an E-AHPBA multi-center study

    HPB, Vol. 21, Núm. 12, pp. 1641-1647

2018

  1. Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study

    Clinical Infectious Diseases, Vol. 66, Núm. 6, pp. 825-832

  2. Staphylococcus aureus CC30 lineage and absence of sed, j,r-harboring plasmid predict embolism in infective endocarditis

    Frontiers in Cellular and Infection Microbiology, Vol. 8, Núm. JUN

2016

  1. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

    Journal of Allergy and Clinical Immunology, Vol. 138, Núm. 6, pp. 1752-1755

  2. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: The point of view of the radiation oncologist

    British Journal of Radiology, Vol. 89, Núm. 1067

2015

  1. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

    JAMA - Journal of the American Medical Association, Vol. 313, Núm. 13, pp. 1347-1361

2012

  1. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Human Mutation, Vol. 33, Núm. 4, pp. 690-702

2011

  1. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

    Journal of the National Cancer Institute, Vol. 103, Núm. 2, pp. 105-116

2010

  1. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction

    Cancer Research, Vol. 70, Núm. 23, pp. 9742-9754